Johnson & Johnson’s ICOTYDE, an oral peptide therapy for moderate to severe plaque psoriasis, was named to TIME’s Best Inventions of 2026 list in the medical and healthcare category. FDA approved in March 2026, the treatment represents a new approach to managing plaque psoriasis, a chronic inflammatory disease. The recognition highlights Johnson & Johnson’s continued efforts to advance treatment options and address unmet needs for patients living with the condition.
